Return to homepagePandemic Pact

75A50122C00076 TRANSFERS THE PROPERTY LISTED WITHIN THE MODIFICATION TO MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO. 2018-843, PROJECT AGREEMENT NO. 1 TO SUPPORT ANALYSIS OF GLYCOPROTEIN VARIANTS IN THE VSV-MARV-GP NEUTRALIZATION ASSAY F

  • Funded by Biomedical Advanced Research and Development Authority (BARDA)
  • Total publications:0 publications

Grant number: 75A50122C00076

Grant search

Key facts

  • Disease

    Marburg virus disease

  • Start & end year

    2022
    2031

  • Known Financial Commitments (USD)

    $110,877,385

  • Funder

    Biomedical Advanced Research and Development Authority (BARDA)

  • Research Location

    United States of America

  • Lead Research Institution

    MAPP BIOPHARMACEUTICAL, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    1v

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

75A50122C00076 TRANSFERS THE PROPERTY LISTED WITHIN THE MODIFICATION TO MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO. 2018-843, PROJECT AGREEMENT NO. 1 TO SUPPORT ANALYSIS OF GLYCOPROTEIN VARIANTS IN THE VSV-MARV-GP NEUTRALIZATION ASSAY F